J&J un­corks long-term da­ta for Crohn's dis­ease can­di­date; Age-re­lat­ed dis­ease biotech earns Eli Lil­ly's back­ing

J&J and Ab­b­Vie are com­pet­ing for the same Crohn’s dis­ease mar­ket with their re­spec­tive IL-23 drugs, Trem­fya and Skyrizi. On Wednes­day, J&J’s Janssen unit re­vealed da­ta it thinks could prove a key dif­fer­en­tia­tor but ap­pears to lack key con­text.

In long-term, Phase II fol­low-up da­ta stretch­ing to 48 weeks, 65% of pa­tients tak­ing Trem­fya saw their Crohn’s dis­ease en­ter clin­i­cal re­mis­sion, J&J an­nounced. The com­pa­ny did not say what pro­por­tion of pa­tients hit re­mis­sion in the place­bo group, how­ev­er, say­ing re­searchers didn’t mea­sure for com­par­i­son to place­bo af­ter week 12.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.